Ature platelet activation.
본문
Serum differs from plasma in that the bulk
Ature platelet activation. Serum differs from plasma in that the bulk of the fibrinogen has been removed by conversion into a fibrin clot together with the platelets that have either been physically bound in the fibrin matrix or activated to form aggregates or both [45]. This finding implies previous blood clotting and therefore platelet activation andSilva et al. BMC Veterinary Research 2012, 8:212 http://www.biomedcentral.com/1746-6148/8/Page 5 ofrelease of the growth factors contained in the platelet alpha granules, including TGF-1. We were not able to find any reports on feline PDGFBB plasma concentration. To the best of our knowledge, this study is the first time that an ELISA human kit for PDGF-BB was used to measure this protein in blood components from cats. However, it is reported that both human and cat PDGF-BB presented high peptide sequence homology [46]. A similar finding has also been noticed between human and equine PDGF-BB [47]. Once the PC is prepared, platelet activation (exogenous or endogenous) may be important to maximize growth factor release. Various substances have been described for the exogenous activation of PC, including thrombin [48], batroxobin [49], collagen type I [50] and calcium chloride [2], among others. The substances most frequently used to activate PC for clinical purposes are thrombin and calcium salts. The use of topical bovine thrombin has been reported in humans to cause the formation of antibodies against the coagulation factor V, prothrombin and thrombin [51]. Reports in mice show the formation of antibodies against autologous clotting factors and the induction of autoimmunity with features characteristic of systemic lupus erythematosus, including antibodies against nuclear antigens, native DNA, double-stranded DNA and cardiolipin [52]. For this reason, the clinical use Fmoc-Oic-OH of bovine thrombin as a platelet activator in feline medicine should be carefully studied. Reports in 4-Bromopicolinaldehyde humans [53] and horses [54] investigated the use of autologous thrombin obtained by the addition of calcium gluconate PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/4155310 to the plasma. PC activation with autologous thrombin might provide another option for clinical practice in cats, and the probability of immunological reactions would be reasonably smaller. In addition, the results of this study reported that CG has an action comparatively equipotent to BT. These reasons suggest the use of CG to induce gelation of the PC for clinical purposes in cats.reported here requires further evaluation in clinical settings.Methods The ethics committee of animal research of Federal University of Minas Gerais approved this study. Owners of the cats included were informed of the nature of the research and signed an authorized consent prior sedation and blood collection.AnimalsSixteen mixed breed cats from local owners were used, specifically, eight males and eight females with an age range between 18 to 108 months and mean body weight of 3.4 kg that were clinically healthy at the time of blood collection. Cats with a basal platelet count less than 300 ?03 PLT/L were not included (normal basal minimum count) [55].Preparation of platelet concentratesAfter the cats were sedated (xylazine, 0.5 mg / kg + butorphanol 0.1 mg / kg, IM), blood was PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21715270 collected by puncturing the jugular vein with a 21 G butterfly catheter. The blood samples were collected into two 8.5 mL tubes containing 1.5 mL of ACD-A solution (trisodium citrate 22 g/L, citric acid 8 g/L and dextrose 24.5 g/L) (Becton Dickinson and Com.
Ature platelet activation. Serum differs from plasma in that the bulk of the fibrinogen has been removed by conversion into a fibrin clot together with the platelets that have either been physically bound in the fibrin matrix or activated to form aggregates or both [45]. This finding implies previous blood clotting and therefore platelet activation andSilva et al. BMC Veterinary Research 2012, 8:212 http://www.biomedcentral.com/1746-6148/8/Page 5 ofrelease of the growth factors contained in the platelet alpha granules, including TGF-1. We were not able to find any reports on feline PDGFBB plasma concentration. To the best of our knowledge, this study is the first time that an ELISA human kit for PDGF-BB was used to measure this protein in blood components from cats. However, it is reported that both human and cat PDGF-BB presented high peptide sequence homology [46]. A similar finding has also been noticed between human and equine PDGF-BB [47]. Once the PC is prepared, platelet activation (exogenous or endogenous) may be important to maximize growth factor release. Various substances have been described for the exogenous activation of PC, including thrombin [48], batroxobin [49], collagen type I [50] and calcium chloride [2], among others. The substances most frequently used to activate PC for clinical purposes are thrombin and calcium salts. The use of topical bovine thrombin has been reported in humans to cause the formation of antibodies against the coagulation factor V, prothrombin and thrombin [51]. Reports in mice show the formation of antibodies against autologous clotting factors and the induction of autoimmunity with features characteristic of systemic lupus erythematosus, including antibodies against nuclear antigens, native DNA, double-stranded DNA and cardiolipin [52]. For this reason, the clinical use Fmoc-Oic-OH of bovine thrombin as a platelet activator in feline medicine should be carefully studied. Reports in 4-Bromopicolinaldehyde humans [53] and horses [54] investigated the use of autologous thrombin obtained by the addition of calcium gluconate PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/4155310 to the plasma. PC activation with autologous thrombin might provide another option for clinical practice in cats, and the probability of immunological reactions would be reasonably smaller. In addition, the results of this study reported that CG has an action comparatively equipotent to BT. These reasons suggest the use of CG to induce gelation of the PC for clinical purposes in cats.reported here requires further evaluation in clinical settings.Methods The ethics committee of animal research of Federal University of Minas Gerais approved this study. Owners of the cats included were informed of the nature of the research and signed an authorized consent prior sedation and blood collection.AnimalsSixteen mixed breed cats from local owners were used, specifically, eight males and eight females with an age range between 18 to 108 months and mean body weight of 3.4 kg that were clinically healthy at the time of blood collection. Cats with a basal platelet count less than 300 ?03 PLT/L were not included (normal basal minimum count) [55].Preparation of platelet concentratesAfter the cats were sedated (xylazine, 0.5 mg / kg + butorphanol 0.1 mg / kg, IM), blood was PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/21715270 collected by puncturing the jugular vein with a 21 G butterfly catheter. The blood samples were collected into two 8.5 mL tubes containing 1.5 mL of ACD-A solution (trisodium citrate 22 g/L, citric acid 8 g/L and dextrose 24.5 g/L) (Becton Dickinson and Com.